Agentix Corp.

AGTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-117.7K $-77.1K $-78.6K $-144.1K $-185.8K $-181.8K $-143.9K $-90.7K
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation — — — — — — — —
Net Cash from Operating Activities $-26.4K $14.8K $-7.9K $3.0K $-118.4K $-43.1K $-87.0K $7.4K
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $0 $0 $0 $0 $0 $0 $0 $0
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $26.3K $0 $10.1K $350 $100.0K $45.0K $25.0K $10.0K
Net Change in Cash $-733 $-5.6K $795 $1.2K $-65 $-3.8K $1.9K $-2.7K
Free Cash Flow — — — — — — — —
← Newer Page 1 of 7 Older →